Evolus (EOLS) Income from Continuing Operations (2017 - 2026)
Evolus (EOLS) posted Income from Continuing Operations of 10674000.0 for Q1 2026, down 8310.77% on a QoQ basis from 130000.0 in Q4 2025, and up 43.5% year-over-year from 7438333.01 in Q1 2025.
Evolus (EOLS) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Evolus' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 10674000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 43.5% year-over-year to 10674000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 43423000.0 (up 22.74% YoY) and the FY2025 annual result came in at 51641000.0, down 2.42% from the prior year.
- Income from Continuing Operations was 10674000.0 for Q1 2026 at Evolus, down from 130000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 130000.0 in Q4 2025 and bottomed at 23471000.0 in Q2 2022.
- A 5-year average of 14637176.47 and a median of 15737000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 373.41% — and 2025, when it soared 101.91%.
- Evolus' Income from Continuing Operations stood at 13164000.0 in 2022, then advanced by 10.13% to 11831000.0 in 2023, then soared by 42.6% to 6791000.0 in 2024, then jumped by 101.91% to 130000.0 in 2025, then plunged by 8310.77% to 10674000.0 in 2026.
- Business Quant data shows EOLS's Income from Continuing Operations at 10674000.0 in Q1 2026, 130000.0 in Q4 2025, and 15737000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn | -10.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.67 Mn |
| Dec 31, 2025 | 130,000.00 |
| Sep 30, 2025 | -15.74 Mn |
| Jun 30, 2025 | -17.14 Mn |
| Mar 31, 2025 | -18.89 Mn |
| Dec 31, 2024 | -6.79 Mn |
| Sep 30, 2024 | -19.17 Mn |
| Jun 30, 2024 | -11.35 Mn |
| Mar 31, 2024 | -13.11 Mn |
| Dec 31, 2023 | -11.83 Mn |
| Sep 30, 2023 | -16.92 Mn |
| Jun 30, 2023 | -18.14 Mn |
| Mar 31, 2023 | -14.79 Mn |
| Dec 31, 2022 | -13.16 Mn |
| Sep 30, 2022 | -20.28 Mn |
| Jun 30, 2022 | -23.47 Mn |
| Mar 31, 2022 | -17.50 Mn |
| Dec 31, 2021 | -18.18 Mn |
| Sep 30, 2021 | -19.43 Mn |
| Jun 30, 2021 | -15.60 Mn |